Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.

Indraccolo S, Lombardi G, Fassan M, Pasqualini L, Giunco S, Marcato R, Gasparini A, Candiotto C, Nalio S, Fiduccia P, Fanelli GN, Pambuku A, Della Puppa A, D'Avella D, Bonaldi L, Gardiman MP, Bertorelle R, De Rossi A, Zagonel V.

Clin Cancer Res. 2018 Dec 4. doi: 10.1158/1078-0432.CCR-18-1892. [Epub ahead of print]

PMID:
30514778
2.

Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?

Loupakis F, Schirripa M, Intini R, Bergamo F, Bertorelle R, Fassan M, Dadduzio V, Merigliano S, Pilati P, Urso ELD, Cillo U, Rugge M, Lonardi S, Zagonel V.

Oncologist. 2019 Feb;24(2):e77-e79. doi: 10.1634/theoncologist.2018-0180. Epub 2018 Aug 17.

PMID:
30120156
3.

Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma.

Lombardi G, Della Puppa A, Gardiman MP, Rossi S, Candiotto C, Zanatta L, Bertorelle R, De Rossi A, Fassan M, Zagonel V.

Neuro Oncol. 2018 Jul 5;20(8):1142-1143. doi: 10.1093/neuonc/noy080. No abstract available.

PMID:
29868765
4.

Author Correction: The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients.

Rampazzo E, Del Bianco P, Bertorelle R, Boso C, Perin A, Spiro G, Bergamo F, Belluco C, Buonadonna A, Palazzari E, Lonardi S, De Paoli A, Pucciarelli S, De Rossi A.

Br J Cancer. 2018 Jun;118(12):1684. doi: 10.1038/s41416-018-0067-0.

5.

The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients.

Rampazzo E, Del Bianco P, Bertorelle R, Boso C, Perin A, Spiro G, Bergamo F, Belluco C, Buonadonna A, Palazzari E, Leonardi S, De Paoli A, Pucciarelli S, De Rossi A.

Br J Cancer. 2018 Mar 20;118(6):878-886. doi: 10.1038/bjc.2017.492. Epub 2018 Feb 15. Erratum in: Br J Cancer. 2018 May 21;:.

6.

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases.

Visentin A, Imbergamo S, Frezzato F, Pizzi M, Bertorelle R, Scomazzon E, Berno T, Riva M, Piva E, Facco M, Piazza F, Semenzato G, Trentin L.

Oncotarget. 2017 Sep 28;8(66):110727-110731. doi: 10.18632/oncotarget.21304. eCollection 2017 Dec 15.

7.

WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia.

Bordin F, Piovan E, Masiero E, Ambesi-Impiombato A, Minuzzo S, Bertorelle R, Sacchetto V, Pilotto G, Basso G, Zanovello P, Amadori A, Tosello V.

Haematologica. 2018 Feb;103(2):266-277. doi: 10.3324/haematol.2017.170431. Epub 2017 Nov 23.

8.

Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.

Ferrara AM, Lombardi G, Pambuku A, Meringolo D, Bertorelle R, Nardin M, Schiavi F, Iacobone M, Opocher G, Zagonel V, Zovato S.

Anticancer Drugs. 2018 Jan;29(1):102-105. doi: 10.1097/CAD.0000000000000570.

PMID:
29099418
9.

LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab.

Bonanno L, De Paoli A, Zulato E, Esposito G, Calabrese F, Favaretto A, Santo A, Conte AD, Chilosi M, Oniga F, Sozzi G, Moro M, Ciccarese F, Nardo G, Bertorelle R, Candiotto C, De Salvo GL, Amadori A, Conte P, Indraccolo S.

Clin Cancer Res. 2017 Jul 1;23(13):3316-3324. doi: 10.1158/1078-0432.CCR-16-2410. Epub 2017 Jan 24.

10.

MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.

Pasello G, Urso L, Mencoboni M, Grosso F, Ceresoli GL, Lunardi F, Vuljan SE, Bertorelle R, Sacchetto V, Ciminale V, Rea F, Favaretto A, Conte P, Calabrese F.

Oncotarget. 2015 Dec 8;6(39):42053-66. doi: 10.18632/oncotarget.5974.

11.

Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature.

Polo V, Zago G, Frega S, Canova F, Bonanno L, Favaretto A, Bonaldi L, Bertorelle R, Conte P, Pasello G.

Am J Case Rep. 2015 Nov 3;16:782-9. Review.

12.

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

Schirripa M, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, Yang D, Marmorino F, Pasquini G, Sensi E, Lupi C, De Maglio G, Borrelli N, Pizzolitto S, Fasola G, Bertorelle R, Rugge M, Fontanini G, Zagonel V, Loupakis F, Falcone A.

Br J Cancer. 2015 Jun 9;112(12):1921-8. doi: 10.1038/bjc.2015.142. Epub 2015 May 5.

13.

Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.

Lombardi G, Corona G, Bellu L, Della Puppa A, Pambuku A, Fiduccia P, Bertorelle R, Gardiman MP, D'Avella D, Toffoli G, Zagonel V.

Oncologist. 2015 May;20(5):562-7. doi: 10.1634/theoncologist.2014-0266. Epub 2015 Apr 10.

14.

Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.

Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L, Gardiman MP, Bertorelle R, Scanarini M, D'Avella D, Occhi G, Boscaro M, Zagonel V, Scaroni C.

J Neurooncol. 2015 Mar;122(1):189-96. doi: 10.1007/s11060-014-1702-0. Epub 2015 Jan 3.

PMID:
25555563
15.

VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells.

Curtarello M, Zulato E, Nardo G, Valtorta S, Guzzo G, Rossi E, Esposito G, Msaki A, Pastò A, Rasola A, Persano L, Ciccarese F, Bertorelle R, Todde S, Plebani M, Schroer H, Walenta S, Mueller-Klieser W, Amadori A, Moresco RM, Indraccolo S.

Cancer Res. 2015 Jan 1;75(1):120-33. doi: 10.1158/0008-5472.CAN-13-2037. Epub 2014 Nov 7.

16.

Adrenocortical tumors in Italian children: analysis of clinical characteristics and P53 status. Data from the national registries.

Dall'Igna P, Virgone C, De Salvo GL, Bertorelle R, Indolfi P, De Paoli A, Buffa P, Conte M, Esposito G, Inserra A, Candiotto C, D'Onofrio V, Boldrini R, Ferrari A, Bisogno G, Alaggio R, Cecchetto G.

J Pediatr Surg. 2014 Sep;49(9):1367-71. doi: 10.1016/j.jpedsurg.2014.03.006.

PMID:
25148739
17.

Multiple sporadic gastrointestinal stromal tumors concomitant with ampullary adenocarcinoma: a case report with KIT and PDGFRA mutational analysis and miR-221/222 expression profile.

Blandamura S, Alessandrini L, Bertorelle R, Simonato F, Guzzardo V, Valentini E, Angriman I, Fassina A.

Pathol Res Pract. 2014 Jun;210(6):392-6. doi: 10.1016/j.prp.2014.01.019. Epub 2014 Mar 5.

PMID:
24674454
18.

Telomeres, telomerase and colorectal cancer.

Bertorelle R, Rampazzo E, Pucciarelli S, Nitti D, De Rossi A.

World J Gastroenterol. 2014 Feb 28;20(8):1940-50. doi: 10.3748/wjg.v20.i8.1940. Review.

19.

Epithelioid rhabdomyosarcoma: a clinicopathologic and molecular study.

Zin A, Bertorelle R, Dall'Igna P, Manzitti C, Gambini C, Bisogno G, Rosolen A, Alaggio R.

Am J Surg Pathol. 2014 Feb;38(2):273-8. doi: 10.1097/PAS.0000000000000105.

PMID:
24418861
20.

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.

Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, Bertorelle R, Manni S, Pavan L, Lessi F, Zambello R, Trentin L, Adami F, Ruzzene M, Pinna LA, Semenzato G, Piazza F.

J Hematol Oncol. 2013 Oct 12;6:78. doi: 10.1186/1756-8722-6-78.

21.

Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma.

Baboci L, Boscolo-Rizzo P, Holzinger D, Bertorelle R, Biasini L, Michel A, Schmitt M, Spinato G, Bussani R, Alemany L, Tirelli G, Da Mosto MC, Del Mistro A, Pawlita M.

Virol J. 2013 Nov 12;10:334. doi: 10.1186/1743-422X-10-334.

22.

Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.

Lombardi G, Rumiato E, Bertorelle R, Saggioro D, Farina P, Della Puppa A, Zustovich F, Berti F, Sacchetto V, Marcato R, Amadori A, Zagonel V.

Am J Clin Oncol. 2015 Oct;38(5):514-9. doi: 10.1097/COC.0b013e3182a790ea.

PMID:
24064758
23.

C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions.

Alessandrini L, Parrozzani R, Bertorelle R, Valentini E, Candiotto C, Giacomelli L, Midena E, Blandamura S.

Acta Ophthalmol. 2013 Dec;91(8):e641-5. doi: 10.1111/aos.12166. Epub 2013 Jun 7.

24.

Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer.

Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Maretto I, Lonardi S, Friso ML, Mescoli C, Zagonel V, Nitti D, De Rossi A, Pucciarelli S.

Br J Cancer. 2013 Feb 5;108(2):278-84. doi: 10.1038/bjc.2012.602. Epub 2013 Jan 15.

25.

Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.

Lombardi G, Zustovich F, Farina P, Fiduccia P, Della Puppa A, Polo V, Bertorelle R, Gardiman MP, Banzato A, Ciccarino P, Denaro L, Zagonel V.

Anticancer Drugs. 2013 Jan;24(1):90-7. doi: 10.1097/CAD.0b013e32835aa5fd. Review.

PMID:
23075631
26.

The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

Cattelani S, Ferrari-Amorotti G, Galavotti S, Defferrari R, Tanno B, Cialfi S, Vergalli J, Fragliasso V, Guerzoni C, Manzotti G, Soliera AR, Menin C, Bertorelle R, McDowell HP, Inserra A, Belli ML, Varesio L, Tweddle D, Tonini GP, Altavista P, Dominici C, Raschellà G, Calabretta B.

Neoplasia. 2012 Jul;14(7):634-43.

27.

Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.

Lombardi G, Zustovich F, Farina P, Polo V, Farina M, Della Puppa A, Bertorelle R, Gardiman MP, Berti F, Zagonel V.

Anticancer Drugs. 2012 Aug;23(7):749-53. doi: 10.1097/CAD.0b013e3283520e2c. Review.

PMID:
22382388
28.

Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy.

Urso E, Agostini M, Pucciarelli S, Rugge M, Bertorelle R, Maretto I, Bedin C, D'Angelo E, Mescoli C, Zorzi M, Viel A, Bruttocao G, Ferraro B, Erroi F, Contin P, De Salvo GL, Nitti D.

Tumour Biol. 2012 Jun;33(3):857-64. doi: 10.1007/s13277-011-0312-0. Epub 2012 Jan 26.

PMID:
22278153
29.

Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes.

Fadini GP, Albiero M, Menegazzo L, Boscaro E, Vigili de Kreutzenberg S, Agostini C, Cabrelle A, Binotto G, Rattazzi M, Bertacco E, Bertorelle R, Biasini L, Mion M, Plebani M, Ceolotto G, Angelini A, Castellani C, Menegolo M, Grego F, Dimmeler S, Seeger F, Zeiher A, Tiengo A, Avogaro A.

Circ Res. 2011 Apr 29;108(9):1112-21. doi: 10.1161/CIRCRESAHA.110.234088. Epub 2011 Mar 10.

PMID:
21393578
30.

Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy.

Spolverato G, Pucciarelli S, Bertorelle R, De Rossi A, Nitti D.

Cancers (Basel). 2011 Apr 26;3(2):2176-94. doi: 10.3390/cancers3022176.

31.

Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.

Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F, Favaretto A.

Anticancer Res. 2010 Dec;30(12):5121-8.

PMID:
21187500
32.

Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers.

Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S, Del Bianco P, Nitti D, De Rossi A.

Br J Cancer. 2010 Apr 13;102(8):1300-5. doi: 10.1038/sj.bjc.6605644.

33.

A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors.

Agostini M, Enzo MV, Morandi L, Bedin C, Pizzini S, Mason S, Bertorelle R, Urso E, Mescoli C, Lise M, Pucciarelli S, Nitti D.

Cancer Biomark. 2010;6(1):49-61. doi: 10.3233/CBM-2009-0118.

PMID:
20164541
34.

Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer.

Nicoletto MO, Bertorelle R, Borgato L, De Salvo GL, Artioli G, Lombardi G, Zustovich F, Marcato R, Parenti A, Montagna M, Donach ME.

Int J Gynecol Cancer. 2009 Aug;19(6):1022-8. doi: 10.1111/IGC.0b013e3181a83cb5.

PMID:
19820363
35.

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.

Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C, Bertorelle R, Scaini MC, Bartel F, Böhnke A, Pempe C, Gradhand E, Hauptmann S, Offit K, Levine AJ, Bond GL.

Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10236-41. doi: 10.1073/pnas.0901298106. Epub 2009 Jun 4. Erratum in: Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12208. Monagna, Marco [corrected to Montagna, Marco].

36.

Gastrointestinal stromal tumors: report of an audit and review of the literature.

Biasco G, Velo D, Angriman I, Astorino M, Baldan A, Baseggio M, Basso U, Battaglia G, Bertin M, Bertorelle R, Bocus P, Brosolo P, Bulzacchi A, Cannizzaro R, Da Dalt GF, Di Battista M, Errante D, Fedrigo M, Frustaci S, Lionetti I, Massani M, Mencarelli R, Montesco MC, Norberto L, Pantaleo MA, Pasquali C, Pastorelli D, Rossi CR, Ruffolo C, Salvagno L, Saponara MS, Vittadello F, Zaccaria F, Zovato S, Farinati F; Section of Oncology of the Italian Society of Gastroenterology; Interdisciplinary GIST Group-G.I.GIST, Veneto Institute of Oncology IOV-IRCCS Azienda Ospedale, University of Padua; GIST Study Group, Bologna University.

Eur J Cancer Prev. 2009 Apr;18(2):106-16. doi: 10.1097/CEJ.0b013e32830c8da8. Review.

PMID:
19337057
37.

Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease.

Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, Esposito G, DelBianco P, Nitti D, De Rossi A.

Clin Cancer Res. 2008 Nov 15;14(22):7444-51. doi: 10.1158/1078-0432.CCR-08-0478.

38.

Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.

Cattelani S, Defferrari R, Marsilio S, Bussolari R, Candini O, Corradini F, Ferrari-Amorotti G, Guerzoni C, Pecorari L, Menin C, Bertorelle R, Altavista P, McDowell HP, Boldrini R, Dominici C, Tonini GP, Raschellà G, Calabretta B.

Clin Cancer Res. 2008 Jun 1;14(11):3248-53. doi: 10.1158/1078-0432.CCR-07-4725.

39.

Proximal colon cancer in patients aged 51-60 years of age should be tested for microsatellites instability. A comment on the Revised Bethesda Guidelines.

Urso E, Pucciarelli S, Agostini M, Maretto I, Mescoli C, Bertorelle R, Viel A, Rugge M, Nitti D.

Int J Colorectal Dis. 2008 Aug;23(8):801-6. doi: 10.1007/s00384-008-0484-2. Epub 2008 Apr 30.

PMID:
18446350
40.

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.

J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163.

PMID:
18445844
41.

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.

Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, Brandes AA.

J Neurooncol. 2008 Sep;89(2):179-85. doi: 10.1007/s11060-008-9600-y. Epub 2008 Apr 23.

PMID:
18431544
42.

Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk.

Schwab R, Bussolari R, Corvetta D, Chayka O, Santilli G, Kwok JM, Ferrari-Amorotti G, Tonini GP, Iacoviello L, Bertorelle R, Menin C, Hubank M, Calabretta B, Sala A.

Oncogene. 2008 May 1;27(20):2929-33. Epub 2007 Nov 19. Erratum in: Oncogene. 2008 May 22;27(23):3360. Amorotti, G F [corrected to Ferrari-Amorotti, G].

PMID:
18026132
43.

A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors.

Zustovich F, Cartei G, Ceravolo R, Zovato S, Della Puppa A, Pastorelli D, Mattiazzi M, Bertorelle R, Gardiman MP.

Anticancer Res. 2007 Mar-Apr;27(2):1019-24.

44.

hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.

Terrin L, Dolcetti R, Corradini I, Indraccolo S, Dal Col J, Bertorelle R, Bonaldi L, Esposito G, De Rossi A.

Int J Cancer. 2007 Aug 1;121(3):576-87.

45.

Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors.

Addeo R, Crisci S, D'Angelo V, Vincenzi B, Casale F, Pettinato G, Donofrio V, Boldrini R, Alaggio R, Collini P, Bertorelle R, Di Tullio MT, Caraglia M, Terenziani M, Lo Curto M, Indolfi P.

Oncol Rep. 2007 May;17(5):1155-61.

PMID:
17390059
46.

Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.

Terrin L, Trentin L, Degan M, Corradini I, Bertorelle R, Carli P, Maschio N, Bo MD, Noventa F, Gattei V, Semenzato G, De Rossi A.

Leukemia. 2007 May;21(5):965-72. Epub 2007 Mar 8.

PMID:
17344921
47.

Human papillomavirus typing of invasive cervical cancers in Italy.

Del Mistro A, Salamanca HF, Trevisan R, Bertorelle R, Parenti A, Bonoldi E, Zambon P, Minucci D.

Infect Agent Cancer. 2006 Dec 27;1:9.

48.

Genital human papillomavirus types in immunocompetent and immunodepressed women in northeast Italy: prevalence and cytomorphological correlations.

Del Mistro A, Bonaldi L, Bertorelle R, Minucci D, Franzetti M, Cattelan A, Bonoldi E, Sposetti R, Torrisi A, Chieco-Bianchi L.

J Low Genit Tract Dis. 2001 Jan;5(1):12-20.

PMID:
17043556
49.

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crinò L, Ermani M; GICNO.

Br J Cancer. 2006 Nov 6;95(9):1155-60. Epub 2006 Oct 3.

50.

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M; GICNO.

J Clin Oncol. 2006 Oct 10;24(29):4746-53. Epub 2006 Sep 5.

PMID:
16954518

Supplemental Content

Loading ...
Support Center